Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.

European journal of clinical pharmacology - 1 Aug 1998

Koytchev R, Alken R G, Vlahov V, Kirkov V, Kaneva R, Thyroff-Friesinger U, Rehak E

Abstract excerpt

AIM: The aim of the present paper was to compare the pharmacokinetics of metoprolol in homozygous Caucasian volunteers for the wild-type CYP2D6 allele (CYP2D6*1/CYP2D6*1) and heterozygous (CYP2D6*1/CYP2D6*4) Caucasians. METHODS: Thirty-six unrelated healthy male Caucasians were screened for two of the most frequently occurring mutant alleles (CYP2D6*3 and CYP2D6*4) using polymerase chain reaction (PCR)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Alleles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Cytochrome P-450 CYP2D6

Share to Heterozygote

Share to Homozygote

Share to Polymerase Chain Reaction

Share to Reference Values

Source

Identifiers

PMID: 9776437
DOI: 10.1007/s002280050495

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.PMID 9776437Read ↗

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.Semantic proximity Read ↗

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.Semantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.Semantic proximity Read ↗

Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.Semantic proximity Read ↗

Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol TartrateSemantic proximity Read ↗

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.Semantic proximity Read ↗

Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.